Fairvalue-Calculator Fairvalue-Calculator
EN DE

Shine-On BioMedical Co (6926) Fair Value & Analysis

Healthcare · TW · Market cap 3.0B TWD

Price63.20 TWD
Fair Value54.66 TWD
Upside-13.5%
Quality95/100
Evidence: Low Range 40.99 TWD – 68.32 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Shine-On BioMedical Co (6926) currently trades at 63.20 TWD, while our model-based Fair Value estimate is 54.66 TWD — implying the stock looks roughly 13.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Shine-On BioMedical Co.,Ltd. research, develops, and manufactures anti-cancer related drug products. It also develops antibody anticancer drugs, such as exosome anti-cancer drugs, that includes SOB101 and SOB102; SOB201 for engineered multi-target exosomes; SOA101, a dual immune checkpoint T cell adapter antibody; and SOA201, a trispecific adapter immune cell antibody. Shine-On BioMedical Co.,Ltd. was founded in 2011 and is based in Taichung, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Shine-On BioMedical Co (6926) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 54.66 TWD versus a price of 63.20 TWD — about −14% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6926?
Our 21-model fair value for Shine-On BioMedical Co is 54.66 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 63.20 TWD.
What is the quality score of 6926?
Shine-On BioMedical Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.